Expansion momentum SERB is actively expanding through strategic acquisitions and asset development deals, including the Y-mAbs acquisition and the Idefirix rights deal, signaling ongoing growth and potential cross-sell opportunities for rare disease therapeutics and antibody-based therapies across new markets.

EU and MENA focus Recent agreements extend development and commercialization rights to Idefirix in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region, presenting targeted geographic entry points for portfolio expansion and partner-led distribution deals.

New product launches Commercial availability of ThyroSafe 130mg potassium iodide tablets in the US demonstrates market readiness and regulatory success, offering a near-term upsell path to hospitals, clinics, and emergency preparedness channels seeking rapid access to critical medicines.

Rare disease focus SERB’s emphasis on life-saving medicines for rare and urgent conditions, coupled with a global 100+ country reach, creates multiple collaboration avenues with specialty distributors, contract manufacturers, and regional healthcare systems looking for reliable, rapid-access solutions.

Leadership engagement Recent CMO appointment and leadership investments indicate a strategic push to scale clinical development and commercialization capabilities, suggesting readiness for co-development partnerships, advisory roles, and clinical trial collaborations to accelerate go-to-market strategies.